TOT BIOPHARM International Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jun Liu
Chief executive officer
CN¥7.5m
Total compensation
| CEO salary percentage | 49.5% |
| CEO tenure | 5.8yrs |
| CEO ownership | n/a |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement
Dec 18
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥9m |
| Mar 31 2024 | n/a | n/a | -CN¥14m |
| Dec 31 2023 | CN¥8m | CN¥4m | -CN¥38m |
| Sep 30 2023 | n/a | n/a | -CN¥44m |
| Jun 30 2023 | n/a | n/a | -CN¥49m |
| Mar 31 2023 | n/a | n/a | -CN¥50m |
| Dec 31 2022 | CN¥5m | CN¥3m | -CN¥50m |
| Sep 30 2022 | n/a | n/a | -CN¥106m |
| Jun 30 2022 | n/a | n/a | -CN¥162m |
| Mar 31 2022 | n/a | n/a | -CN¥212m |
| Dec 31 2021 | CN¥3m | CN¥2m | -CN¥261m |
Compensation vs Market: Jun's total compensation ($USD1.03M) is above average for companies of similar size in the Hong Kong market ($USD348.00K).
Compensation vs Earnings: Jun's compensation has been consistent with company performance over the past year.
CEO
Jun Liu (56 yo)
5.8yrs
Tenure
CN¥7,528,000
Compensation
Dr. Jun Liu serves as Chief Executive Officer at TOT BIOPHARM International Company Limited since October 15, 2020 and serves as its Executive Director since October 26, 2018. Dr. Liu serves as Chief Scien...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Executive Director | 5.8yrs | CN¥7.53m | no data | |
| Executive Finance Director | 2.8yrs | no data | no data | |
| Joint Company Secretary | 5.7yrs | no data | no data | |
| Joint Company Secretary | 2.8yrs | no data | no data |
4.3yrs
Average Tenure
43yo
Average Age
Experienced Management: 1875's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Executive Director | 6.2yrs | CN¥7.53m | no data | |
| Chairman of the Board | 8.9yrs | no data | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥282.00k | no data | |
| Non-Executive Vice Chairman of the Board | 8.9yrs | CN¥600.00k | 0.71% HK$ 8.7m | |
| Independent Non-Executive Director | 5.8yrs | CN¥282.00k | no data | |
| Non-Executive Director | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | 2.8yrs | CN¥282.00k | no data |
5.8yrs
Average Tenure
56yo
Average Age
Experienced Board: 1875's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TOT BIOPHARM International Company Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Qiu Lin | Guoyuan Securities (HK) Ltd |
| Yue-Kwong Lui | Jefferies LLC |